Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7308-7318

  Lamoureux, François ^a,b   Richard, Peggy ^a   Wittrant, Yohann ^a,b   Battaglia, Séverine ^a,b   Pilet, Paul ^a   Trichet, Valérie ^a,b   Blanchard, Frédéric ^a,b   Gouin, François ^c   Pitard, Bruno ^a   Heymann, Dominique ^a,b   Redini, Françoise ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOPTOSIS INDUCING FACTOR; COMPLEMENTARY DNA; OSTEOPROTEGERIN; POLYMER; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE ATROPHY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE REPLICATION; GENE TRANSFER; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; CASPASES; CELL CYCLE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; MALE; MICE; MICE, INBRED C3H; MYOBLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; OSTEOSARCOMA; RANK LIGAND; RATS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547629223     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4130     Document Type: Article

References (46)

1. Bell W, Siegal GP. Osteosarcoma. In: Cullinane C, Burchill S, Squire J, Lewis I, O'Leary J, editors. Molecular biology and pathology of pediatric cancer. London, Oxford University Press; 2002.
2. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-78.
3. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Rédini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457-75.
4. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-5.
5. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
6. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-nB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-70.
7. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor nB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163:2021-31.
8. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8.
9. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-36.
10. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
11. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40.
12. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
13. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6.
14. Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van HL, Lacey DL. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 2000;18:967-76.
15. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47.
16. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant Osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.
17. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-102.
18. Bolon B, Carter C, Daris M, et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001;3:197-205.
19. Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther 2002;13:1767-75.
20. Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004;32:e159.
21. Desigaux L, Gourden C, Bello-Roufai M, et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther 2005;16:821-9.
22. Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther 2005;16:1318-24.
23. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 2002;188:213-9.
24. Cherrier B, Gouin F, Heymann MF, et al. A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol 2005;26:121-30.
25. Yaffe D, Saxel O. A myogenic cell line with altered serum requirements for differentiation. Differentiation 1977;7:159-66.
26. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006;28:261-9.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
28. Thiéry J-P, Perdereau B, Gongora R, Gongora G, Mazabraud A. Un modèle experimental d'ostéosarcome chez le rat. II. L'ostéosarcome greffable du rat. Sem Hôp Paris 1982;58:1686-9.
29. Pollard H, Remy S, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem 1998;273:7507-11.
30. Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86.
31. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J, Väänänen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-54.
32. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003;41:1052-59.
33. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-7.
34. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
35. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
36. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci 2006;110:279-91.
37. Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006;66:3620-8.
38. Kostenuik PJ, Bolon B, Morony S, et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64.
39. Yang SY, Mayton L, Wu B, Goater JJ, Schwartz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002;46:2514-23.
40. Atkins GJ, Bouralexis S, Haynes DR, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumor of bone. Bone 2001;28:370-7.
41. Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Met 2004;21:381-7.
42. Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005;65:1710-8.
43. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-7.
44. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007;67:202-9.
45. Paget S. The distrubution of secondary growths in cancer of the breast. Lancet 1889;1:571-2.
46. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004;4:308-18.